<DOC>
	<DOCNO>NCT02395549</DOCNO>
	<brief_summary>This study design investigate efficacy , safety tolerability MTC896 Gel subject acne . In study , MTC896 Gel apply 3 concentration , twice daily ( bid ) 12 week compare vehicle control .</brief_summary>
	<brief_title>A Study Determine Efficacy Topically Applied MTC896 Gel Subjects With Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>1 . Is male nonpregnant , nonlactating , nonbreastfeeding female , 16 65 year age , inclusive , time screening ; 2 . Has provide write informed consent/assent ( include consent photograph , applicable , take Baseline endoftreatment/endofstudy [ EOT/EOS ] visit ) ; 3 . Has diagnose mildtosevere acne vulgaris define : At least 20 inflammatory lesion , At least 20 noninflammatory lesion , ≤ 2 nodular lesion , Investigator Global Assessment 2 great ; 4 . Is willing comply requirement protocol ; 5 . If female childbearing potential premenarcheal , negative urine pregnancy test Screening Baseline / Day 1 willing use effective contraception study 30 day last study medication application . Females consider childbearing potential unless surgically sterilize ( hysterectomy , bilateral oophorectomy , tubal ligation ) , diagnose infertile , postmenopausal least 1 year ; ( Acceptable method birth control define : abstinence , oral contraceptive , contraceptive patches/implants , DepoProvera® , double barrier method ( e.g . condom spermicide ) intrauterine device ( IUD ) . Birth control method must stable/unchanged 12 week prior Baseline must remain unchanged study participation ) ; 6 . If male , vasectomized agrees use accepted method birth control female partner study participation 30 day last study medication application ; 7 . Is good health free disease , opinion Investigator , would put subject risk participate study ; 8 . Is free systemic dermatologic disorder , , opinion Investigator , interfere study result increase risk adverse event ; 9 . Is willing abstain use facial treatment product face study ( continue use makeup permit may change within 2 week prior study period entire study period ) ; 10 . Is willing avoid sun exposure protect face hat/visor ; sunscreen use recommended/allowed sun exposure avoid ; 11 . If male , must agree shave treatment area must agree alter routine shave regimen duration study ; 12 . Is willing refrain use treatment , study medication , include antibiotic , acne present face . Topical acne treatment significant measurable systemic absorption ( e.g . benzoyl peroxide , salicylic acid ) allow treatment acne back , shoulder , chest . 1 . People would otherwise qualify study , live household study subject , allow participate study ; 2 . Pregnant lactating plan become pregnant within 1 month ( 30 day ) study completion ; 3 . Known allergy/sensitivity study medication component ; 4 . Any skin condition may interfere evaluation safety acne vulgaris ( e.g . rosacea , seborrheic dermatitis , perioral dermatitis , corticosteroidinduced acne folliculitis ) ; 5 . Excessive facial hair would interfere diagnosis assessment acne vulgaris ; 6 . Excessive sun exposure , opinion Investigator , use tanning booth ; 7 . Active cystic acne acne conglobata , acne fulminans , secondary acne ; 8 . Screening clinical chemistry hematology laboratory value consider clinically significant , opinion Investigator ; 9 . Participation investigational drug study within 30 day prior Screening ; 10 . Is poor medical risk systemic disease active uncontrolled infection , opinion Investigator ; 11 . Any condition , judgment Investigator , would put subject unacceptable risk participation study ; 12 . Within 9 month ( 270 day ) prior Baseline throughout study : Oral retinoid use ( e.g . isotretinoin ) ; 13 . Within 6 month ( 180 day ) prior Baseline throughout study : Treatment Vitamin A supplement great 10,000 units/day ; 14 . Within 3 month ( 90 day ) prior Baseline throughout study : Use androgen receptor blocker ( spironolactone flutamide ) ; Initiation treatment hormonal therapy dose change hormonal therapy ; Dose frequency use hormonal therapy start 3 month ( 90 day ) prior Baseline must remain unchanged throughout study ; Hormonal therapy include , limited , testosterone , anabolic steroid , birth control pills ; 15 . Within 8 week ( 56 day ) prior Baseline throughout study : Facial procedure ( chemical laser peel , microdermabrasion , etc . ) ; 16 . Within 4 week ( 28 day ) prior Baseline throughout study : Treatment systemic corticosteroid ( include intranasal inhaled corticosteroid ) ; Treatment systemic antibiotic systemic antiacne drug systemic antiinflammatory drug ; Note : Nonsteroidal antiinflammatory drug ( NSAIDs ) aspirin use asneeded basis use consecutively &gt; 14 day prior Baseline acceptable require washout . Low dose ( 81 mg ) aspirin take daily acceptable . Prescription topical retinoid use face ( e.g . tretinoin , tazarotene , adapalene ) ; Antifungals , antiretrovirals antibiotic include CYP 3A4 CYP 3A5 ; 17 . Within 2 week ( 14 day ) prior Baseline throughout study : Treatment topical prescription antibiotic ( e.g . dapsone , clindamycin , erythromycin , sulfacetamide ) ; Treatment overthecounter ( OTC ) topical medication treatment acne vulgaris include benzoyl peroxide , topical antiinflammatory medication , corticosteroid , αhydroxy/glycolic acid face ; 18 . Within 1 day prior Baseline throughout study : Grapefruit juice include CYP 3A4 CYP 3A5 .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>